D-AP5 (mM/ml), NMDA glutamate site antagonist (ab144482)
Key features and details
- NMDA glutamate site antagonist. 1 ml water soluble pack.
- CAS Number: 79055-68-8
- Purity: > 99%
- Soluble in 1 ml of water to give specified mM/ml concentration
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
D-AP5 (mM/ml), NMDA glutamate site antagonist -
Description
NMDA glutamate site antagonist. 1 ml water soluble pack. -
Alternative names
- APV
- D-APV
-
Biological description
Competitive NMDA receptor glutamate site antagonist. More active form of DL-AP5.
Soluble in 1 ml water to give specified mM/ml concentration. Find out more. -
Purity
> 99% -
CAS Number
79055-68-8 -
Chemical structure
Properties
-
Chemical name
D-(-)-2-Amino-5-phosphonopentanoic acid -
Molecular weight
197.13 -
Molecular formula
C5H12NO5P -
PubChem identifier
135342 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in 1 ml of water to give specified mM/ml concentration -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
N[C@H](CCCP(=O)(O)O)C(=O)O -
Source
Synthetic
-
Research areas
Images
-
Functional Studies - D-AP5 (mM/ml), NMDA glutamate site antagonist (ab144482) Case et al PLoS One. 2011;6(6):e20756. doi: 10.1371/journal.pone.0020756. Epub 2011 Jun 9. Fig 3. Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/
Fractional current mediated by AMPARs increases between birth and hearing onset.
A: Representative mixed glutamatergic responses from P1, P5 and P9 neurons (average of 10 recordings), scaled to peak AMPA current; distinct AMPA and NMDA components visible in each trace. B: Same traces as in A, showing the mixed glutamatergic current, the pharmacologically isolated NMDAR component, and the response after application of AMPAR and NMDAR antagonists, D-APV and CNQX, which abolishes the glutamatergic response. All recordings in Mg++-free ACSF. Note change in scalebars for P9 recordings. C: Ratios of peak AMPA/NMDA current in 39 cells from slices P1-P12. During this period, AMPA/NMDA ratio increases as a function of age (p = 0.012, Kruskal-Wallis; P1/2 vs P9/10, p = 0.048; P7/8 vs P9/10, p = 0.30; P9/10 vs P11/12 p = 0.010; linear regression slope 0.14/day, r2 = 0.32; exponential fit r2 = 0.36). Filled black circles represent means ± SEMs at two-day intervals. Filled gray circles represent cells shown in A,B. D: Increase in AMPA/NMDA ratio with age is accompanied by small increases in average AMPA current (open circles, regressed to gray line) and decreases in average NMDAR current (filled circles, regressed to black line).
